Literature DB >> 30485112

The Role of PEG-40-stearate in the Production, Morphology, and Stability of Microbubbles.

Joshua Owen1, Sukanta Kamila2, Shamit Shrivastava1, Dario Carugo3, Jorge Bernardino de la Serna4, Christophoros Mannaris1, Valerio Pereno1, Richard Browning1, Estelle Beguin1, Anthony P McHale2, John F Callan2, Eleanor Stride1.   

Abstract

Phospholipid coated microbubbles are currently in widespread clinical use as ultrasound contrast agents and under investigation for therapeutic applications. Previous studies have demonstrated the importance of the coating nanostructure in determining microbubble stability and its dependence upon both composition and processing method. While the influence of different phospholipids has been widely investigated, the role of other constituents such as emulsifiers has received comparatively little attention. Herein, we present an examination of the impact of polyethylene glycol (PEG) derivatives upon microbubble structure and properties. We present data using both pegylated phospholipids and a fluorescent PEG-40-stearate analogue synthesized in-house to directly observe its distribution in the microbubble coating. We examined microbubbles of clinically relevant sizes, investigating both their surface properties and population size distribution and stability. Domain formation was observed only on the surface of larger microbubbles, which were found to contain a higher concentration of PEG-40-stearate. Lipid analogue dyes were also found to influence domain formation compared with PEG-40-stearate alone. "Squeezing out" of PEG-40-stearate was not observed from any of the microbubble sizes investigated. At ambient temperature, microbubbles formulated with DSPE-PEG(2000) were found to be more stable than those containing PEG-40-stearate. At 37 °C, however, the stability in serum was found to be the same for both formulations, and no difference in acoustic backscatter was detected. This could potentially reduce the cost of PEGylated microbubbles and facilitate simpler attachment of targeting or therapeutic species. However, whether PEG-40-stearate sufficiently shields microbubbles to inhibit physiological clearance mechanisms still requires investigation.

Entities:  

Year:  2018        PMID: 30485112     DOI: 10.1021/acs.langmuir.8b02516

Source DB:  PubMed          Journal:  Langmuir        ISSN: 0743-7463            Impact factor:   3.882


  5 in total

1.  Preserving the Integrity of Surfactant-Stabilized Microbubble Membranes for Localized Oxygen Delivery.

Authors:  Brian E Oeffinger; Purva Vaidya; Iman Ayaz; Rawan Shraim; John R Eisenbrey; Margaret A Wheatley
Journal:  Langmuir       Date:  2019-03-14       Impact factor: 3.882

2.  Bifunctional Therapeutic Application of Low-Frequency Ultrasound Associated with Zinc Phthalocyanine-Loaded Micelles.

Authors:  Yugo A Martins; Maria J V Fonseca; Theo Z Pavan; Renata F V Lopez
Journal:  Int J Nanomedicine       Date:  2020-10-20

3.  Ligand Distribution and Lipid Phase Behavior in Phospholipid-Coated Microbubbles and Monolayers.

Authors:  Simone A G Langeveld; Christian Schwieger; Inés Beekers; Jacob Blaffert; Tom van Rooij; Alfred Blume; Klazina Kooiman
Journal:  Langmuir       Date:  2020-03-18       Impact factor: 3.882

4.  Temporal stability of lipid-shelled microbubbles during acoustically-mediated blood-brain barrier opening.

Authors:  Antonios N Pouliopoulos; Daniella A Jimenez; Alexander Frank; Alexander Robertson; Lin Zhang; Alina R Kline-Schoder; Vividha Bhaskar; Mitra Harpale; Elizabeth Caso; Nicholas Papapanou; Rachel Anderson; Rachel Li; Elisa E Konofagou
Journal:  Front Phys       Date:  2020-05-06

5.  Bactericidal and anti-biofilm effects of uncharged and cationic ultrasound-responsive nitric oxide microbubbles on Pseudomonas aeruginosa biofilms.

Authors:  Gareth LuTheryn; Charlotte Hind; Christopher Campbell; Aaron Crowther; Qiang Wu; Sara B Keller; Peter Glynne-Jones; J Mark Sutton; Jeremy S Webb; Michael Gray; Sandra A Wilks; Eleanor Stride; Dario Carugo
Journal:  Front Cell Infect Microbiol       Date:  2022-08-04       Impact factor: 6.073

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.